LP
BBIO icon

Longaeva Partners’s BridgeBio Pharma BBIO Stock Holding History

Longaeva Partners’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14M Buy
+187,863
New +$13.2M 0.31% 91

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Longaeva Partners's BBIO Position: Q2 2026 in Review

Longaeva Partners opened a new position in BridgeBio Pharma (BBIO) in Q2 2026: 187,863 shares worth $14M. The stake represents 0.31% of the portfolio and ranks #91 among its holdings.

474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Longaeva Partners held 187,863 shares of BridgeBio Pharma worth $14M as of Q2 2026.
  • BridgeBio Pharma was a new Longaeva Partners position in Q2 2026.
  • BridgeBio Pharma made up 0.31% of Longaeva Partners's portfolio in Q2 2026, its #91 holding.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Longaeva Partners's 13F filing for Q2 2026, filed 14 Aug 2026.